Dr. Paul A. MacAry
Paul MacAry received his BSc (Hons) in Molecular Biology from Glasgow University in 1992, his PhD in Immunology from GKT, University of London in 1998 followed by Wellcome Trust postdoctoral fellowship positions in Cambridge University until 2005. Since 2005 he has been an independent investigator in the Department of Microbiology and Immunology at the National University of Singapore (NUS). The multi-disciplinary research in his laboratory covers the entire spectrum of scientific endeavour, from basic research to industrial applications with an emphasis on antibody biology, immune repertoire mapping and protein engineering. Paul was a founding member of the Singaporean Society of Immunologists (SgSI)-Singapore’s first international learned society (www.sgsi.org.sg/) and the founding scientist for three biotechnology companies, BSCR LTD founded in Cambridge in 2004, Antibody Cradle LTD founded in Singapore in 2012 and Singapore MABs LTD founded in 2016. Paul is also a founding member and Associate Editor of Nature Vaccines (www.nature.com/npjvaccines/), a member of the Faculty of 1000 (https://f1000.com/) and his research has been featured in covering articles on the BBC, CNN and Reuters.
Director, Life Sciences Institute. The Life Sciences Institute (LSI) is a research centre dedicated to the understanding of fundamental biological pathways in human health and disease, environmental science and industrial processes. We promote scientific discovery through creative and multidisciplinary approaches in an environment that is highly collaborative. We also seek to integrate our pioneering basic research with the application and exploitation of new research discoveries. LSI brings together scientists and clinicians from five NUS faculties and supports advanced core facilities and cutting-edge research infrastructure.
Chairman (co), NUS-HUJ-CREATE Cellular and Molecular Mechanisms of Inflammation Programme. The NUS-HUJ-CREATE programme started in July 2010 and is a research programme funded by the National Research Foundation (NRF), under its Campus for Research Excellence and Technological Enterprise (CREATE) programme. A total of 23 researchers are working in this programme. They consist of post-doctoral fellows, research associates, research assistants and PhD students. Leading the research teams are a total of 10 Principal Investigators (PIs), 5 from NUS, and 5 from Hebrew University of Jerusalem that hold joint appointments with NUS. The goal of this programme is to accelerate the development of diagnostic and prognostic indicators and novel therapeutics for common inflammatory diseases in Asia.
Founding Member of the Singapore Society of Immunologists (SgSI). This is Singapore’s first major learned society and will have a growing impact on the country’s international reputation for Biomedical research in Immunology and immunotherapy.
Founding Scientist of B.S.C.R. Ltd (2004). Founder and Non-Executive Director of the British Stem Cell Registry Ltd (BSCR Ltd). The company is based on patented pathogen screening technology I developed and patented in 2004 (patent application number GB0412861.7).
Founding Scientist of Antibody Cradle PTE Ltd (2012).
Founding Scientist of Singapore Mabs PTE Ltd (2016). This biotech company was founded with Professor Claudio Cuello (McGill University) to commercialize the antibody repository from the National University of Singapore. The antibodies from NUS are blended with those from the McGill repository in a single catalogue and sold globally as research reagents. The current catalogue comprises over 1000 monoclonal hybridomas.